Current Report Filing (8-k)
April 12 2022 - 9:01AM
Edgar (US Regulatory)
0001293310
false
0001293310
2022-04-12
2022-04-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 12, 2022
Humanigen, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-35798 |
|
77-0557236 |
(State or other Jurisdiction of
Incorporation) |
|
(Commission File No.) |
|
(IRS Employer Identification No.)
|
830
Morris Turnpike, 4th Floor
Short
Hills, New Jersey 07078
(Address of principal executive offices, including
zip code)
(973) 200-3010
(Registrant’s telephone number, including
area code)
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock |
HGEN |
The Nasdaq Stock Market LLC |
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule
12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 7.01. | Regulation FD Disclosure |
A copy of the presentation
Humanigen, Inc. (the “Company”) will use during its meetings with investors commencing April 12, 2022 is furnished as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated herein by reference. In addition, this presentation will be made available
on the Company's website, www.humanigen.com.
Certain Information
The information in this Item 7.01, including
Exhibit 99.1, is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, except to the extent expressly
set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Humanigen, Inc. |
|
|
|
By: |
/s/ Cameron Durrant |
|
|
|
Name: Cameron Durrant
Title: Chairman of the Board and Chief Executive Officer |
Dated: April 12, 2022
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024